{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ09038",
      "entity_text" : "anti-PD-1 antibody",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ09032",
      "entity_text" : "Nivolumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Immune checkpoint inhibitors such as Ipilimumab, the CTLA-4 antibody, and Nivolumab, an anti-PD-1 antibody, have been increasingly used in cancers such as metastatic melanoma and renal cell carcinoma but have been associated with several IMAE, including a high incidence of diarrhea and colitis [XREF_BIBR].",
  "reading_complete" : "2020-08-08T20:05:03Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T20:03:36Z",
  "trigger" : "inhibitors",
  "evidence" : [ "inhibitors such as Ipilimumab, the CTLA-4 antibody, and Nivolumab, an anti-PD-1 antibody" ],
  "pmc_id" : "6347649",
  "score" : 0
}